Assessment of the Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in Patients at High-Risk for Vascular Outcomes – Rationale and Design of the ACCELERATE Trial
Conclusions ACCELERATE will establish whether the CETP inhibition by evacetrapib improves cardiovascular outcomes in patients with high risk vascular disease.
Source: American Heart Journal - Category: Cardiology Source Type: research
More News: Accidents | Cardiology | Cardiovascular | Cholesterol | Diabetes | Endocrinology | Heart | Heart Attack | Ischemic Stroke | Men | Peripheral Vascular Disease (PVD) | Stroke | Study